|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: IL8 |
Gene summary for IL8 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | IL8 | Gene ID | 3576 |
| Gene name | C-X-C motif chemokine ligand 8 | |
| Gene Alias | GCP-1 | |
| Cytomap | 4q13.3 | |
| Gene Type | protein-coding | GO ID | GO:0001525 | UniProtAcc | A0A024RDA5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 3576 | IL8 | Pt13.a | Human | Liver | HCC | 8.72e-28 | 8.15e-01 | 0.021 |
| 3576 | IL8 | Pt13.b | Human | Liver | HCC | 6.11e-48 | 1.19e+00 | 0.0251 |
| 3576 | IL8 | Pt13.c | Human | Liver | HCC | 6.11e-10 | 5.72e-01 | 0.0076 |
| 3576 | IL8 | Pt14.d | Human | Liver | HCC | 1.05e-09 | 3.67e-01 | 0.0143 |
| 3576 | IL8 | P1_S1_AK | Human | Skin | AK | 4.80e-27 | -8.45e-01 | -0.3399 |
| 3576 | IL8 | P2_S3_AK | Human | Skin | AK | 3.30e-28 | -8.45e-01 | -0.3287 |
| 3576 | IL8 | P2_S4_SCCIS | Human | Skin | SCCIS | 2.83e-26 | -8.45e-01 | -0.3043 |
| 3576 | IL8 | P3_S6_AK | Human | Skin | AK | 3.30e-28 | -8.45e-01 | -0.3256 |
| 3576 | IL8 | P4_S8_cSCC | Human | Skin | cSCC | 2.90e-18 | -8.45e-01 | -0.3095 |
| 3576 | IL8 | P5_S10_cSCC | Human | Skin | cSCC | 3.30e-28 | -8.45e-01 | -0.299 |
| 3576 | IL8 | P1_cSCC | Human | Skin | cSCC | 1.05e-12 | -5.84e-01 | 0.0292 |
| 3576 | IL8 | P2_cSCC | Human | Skin | cSCC | 2.36e-14 | -6.43e-01 | -0.024 |
| 3576 | IL8 | P4_cSCC | Human | Skin | cSCC | 1.02e-06 | -6.85e-01 | -0.00290000000000005 |
| 3576 | IL8 | cSCC_p1 | Human | Skin | cSCC | 3.30e-28 | -8.45e-01 | -0.1916 |
| 3576 | IL8 | cSCC_p10 | Human | Skin | cSCC | 3.30e-28 | -8.45e-01 | -0.2095 |
| 3576 | IL8 | cSCC_p11 | Human | Skin | cSCC | 1.97e-27 | -8.45e-01 | -0.2102 |
| 3576 | IL8 | cSCC_p3 | Human | Skin | cSCC | 3.30e-28 | -8.45e-01 | -0.2085 |
| 3576 | IL8 | cSCC_p4 | Human | Skin | cSCC | 2.26e-24 | -8.45e-01 | -0.2022 |
| 3576 | IL8 | cSCC_p6 | Human | Skin | cSCC | 1.17e-26 | -8.45e-01 | -0.1989 |
| 3576 | IL8 | cSCC_p7 | Human | Skin | cSCC | 2.26e-24 | -8.45e-01 | -0.2332 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0465751 | Breast | DCIS | IL-17 signaling pathway | 18/846 | 94/8465 | 4.95e-03 | 2.67e-02 | 1.96e-02 | 18 |
| hsa0513311 | Breast | DCIS | Pertussis | 15/846 | 76/8465 | 7.42e-03 | 3.48e-02 | 2.56e-02 | 15 |
| hsa0517120 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
| hsa0493218 | Cervix | CC | Non-alcoholic fatty liver disease | 58/1267 | 155/8465 | 3.58e-12 | 1.05e-10 | 6.23e-11 | 58 |
| hsa0513020 | Cervix | CC | Pathogenic Escherichia coli infection | 63/1267 | 197/8465 | 9.28e-10 | 2.00e-08 | 1.19e-08 | 63 |
| hsa0513220 | Cervix | CC | Salmonella infection | 74/1267 | 249/8465 | 1.33e-09 | 2.54e-08 | 1.50e-08 | 74 |
| hsa0541720 | Cervix | CC | Lipid and atherosclerosis | 65/1267 | 215/8465 | 6.47e-09 | 1.10e-07 | 6.52e-08 | 65 |
| hsa0516720 | Cervix | CC | Kaposi sarcoma-associated herpesvirus infection | 60/1267 | 194/8465 | 9.74e-09 | 1.58e-07 | 9.33e-08 | 60 |
| hsa0516318 | Cervix | CC | Human cytomegalovirus infection | 65/1267 | 225/8465 | 4.59e-08 | 6.47e-07 | 3.83e-07 | 65 |
| hsa0513120 | Cervix | CC | Shigellosis | 69/1267 | 247/8465 | 7.64e-08 | 1.03e-06 | 6.10e-07 | 69 |
| hsa0421810 | Cervix | CC | Cellular senescence | 49/1267 | 156/8465 | 1.30e-07 | 1.63e-06 | 9.61e-07 | 49 |
| hsa0465718 | Cervix | CC | IL-17 signaling pathway | 31/1267 | 94/8465 | 8.71e-06 | 7.43e-05 | 4.39e-05 | 31 |
| hsa0513516 | Cervix | CC | Yersinia infection | 39/1267 | 137/8465 | 3.27e-05 | 2.41e-04 | 1.42e-04 | 39 |
| hsa051207 | Cervix | CC | Epithelial cell signaling in Helicobacter pylori infection | 24/1267 | 70/8465 | 4.35e-05 | 3.09e-04 | 1.83e-04 | 24 |
| hsa0513416 | Cervix | CC | Legionellosis | 20/1267 | 57/8465 | 1.29e-04 | 8.19e-04 | 4.85e-04 | 20 |
| hsa052197 | Cervix | CC | Bladder cancer | 16/1267 | 41/8465 | 1.45e-04 | 9.05e-04 | 5.35e-04 | 16 |
| hsa0516414 | Cervix | CC | Influenza A | 43/1267 | 171/8465 | 3.03e-04 | 1.64e-03 | 9.68e-04 | 43 |
| hsa051465 | Cervix | CC | Amoebiasis | 29/1267 | 102/8465 | 3.31e-04 | 1.70e-03 | 1.01e-03 | 29 |
| hsa0532314 | Cervix | CC | Rheumatoid arthritis | 27/1267 | 93/8465 | 3.64e-04 | 1.82e-03 | 1.07e-03 | 27 |
| hsa051337 | Cervix | CC | Pertussis | 21/1267 | 76/8465 | 3.08e-03 | 1.19e-02 | 7.03e-03 | 21 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |